Aino Health (AINO) Q3 2026 earnings summary

Executive summary

• Q3 net sales rose 5.6% YoY to KSEK 6,164, while loss after financial items widened to KSEK 1,976 from KSEK 1,292.

• Strategic focus remains on recurring SaaS growth, implementation of new customers, partner-led scalability and operational discipline.

• HUS Group agreement announced 5 November is expected to add ~26,500 users after implementation, taking subscriptions from ~116,000 to ~142,500.

Financial highlights

• Q3 2026 net sales were KSEK 6,164 vs. KSEK 5,838 YoY; operating loss was KSEK 1,573 vs. KSEK 1,027.

• Q3 loss after financial items and net loss were KSEK 1,976 vs. KSEK 1,292; EPS was SEK -0.0 in both periods.

• 9M net sales were KSEK 18,400 vs. KSEK 20,686; operating loss was KSEK 5,981 vs. KSEK 1,788 and net loss was KSEK 6,791 vs. KSEK 2,433.

• Q3 other external costs increased to KSEK 3,136 from KSEK 1,896; employee benefit costs were KSEK 3,782 vs. KSEK 3,848.

Outlook and guidance

• Priorities for the remaining months of 2026 include implementing new customers, converting the sales pipeline into SaaS growth, building partner channels and maintaining financial discipline.

• Earlier customer agreements are progressing through implementation, with revenue contributions increasing gradually as deployments proceed.

• The HUS Group agreement has an estimated value of ~€520,000 excluding VAT over the initial 24-month fixed term, based on an assumed 26,500 users.